LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells

Página do item simplificado
dc.contributor.authorPereira, Isadora Oliveira Ansaloni
dc.contributor.authorda Silva, Glenda Nicioli
dc.contributor.authorAlmeida, Tamires Cunha
dc.contributor.authorLima, Ana Paula Braga
dc.contributor.authorSávio, André Luiz Ventura
dc.contributor.authorLeite, Katia Ramos Moreira
dc.contributor.authorSalvadori, Daisy Maria Fávero [UNESP]
dc.contributor.institutionUFOP—Federal University of Ouro Preto
dc.contributor.institutionButantan Institute
dc.contributor.institutionFaculdade do Centro Oeste Paulista—FACOP
dc.contributor.institutionUniversidade do Oeste Paulista—UNOESTE
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.date.accessioned2023-07-29T13:45:53Z
dc.date.available2023-07-29T13:45:53Z
dc.date.issued2023-03-01
dc.description.abstractLong non-coding RNAs are frequently found to be dysregulated and are linked to carcinogenesis, aggressiveness, and chemoresistance in a variety of tumors. As expression levels of the JHDM1D gene and lncRNA JHDM1D-AS1 are altered in bladder tumors, we sought to use their combined expression to distinguish between low-and high-grade bladder tumors by RTq-PCR. In addition, we evaluated the functional role of JHDM1D-AS1 and its association with the modulation of gemcitabine sensitivity in high-grade bladder-tumor cells. J82 and UM-UC-3 cells were treated with siRNA-JHDM1D-AS1 and/or three concentrations of gemcitabine (0.39, 0.78, and 1.56 µM), and then submitted to cytotoxicity testing (XTT), clonogenic survival, cell cycle progression, cell morphology, and cell migration assays. When JHDM1D and JHDM1D-AS1 expression levels were used in combination, our findings indicated favorable prognostic value. Furthermore, the combined treatment resulted in greater cytotoxicity, a decrease in clone formation, G0/G1 cell cycle arrest, morphological alterations, and a reduction in cell migration capacity in both lineages compared to the treatments alone. Thus, silencing of JHDM1D-AS1 reduced the growth and proliferation of high-grade bladder-tumor cells and increased their sensitivity to gemcitabine treatment. In addition, the expression of JHDM1D/JHDM1D-AS1 indicated potential prognostic value in the progression of bladder tumors.en
dc.description.affiliationDepartamento de Análises Clínicas Pharmacy School UFOP—Federal University of Ouro Preto, MG
dc.description.affiliationLaboratory of Pain and Signaling Butantan Institute, SP
dc.description.affiliationDepartamento de Odontologia Faculdade do Centro Oeste Paulista—FACOP, SP
dc.description.affiliationDepartamento de Ciências Médicas Universidade do Oeste Paulista—UNOESTE, SP
dc.description.affiliationDepartamento de Cirurgia Medical School USP—University of São Paulo, SP
dc.description.affiliationDepartamento de Patologia Medical School UNESP—São Paulo State University, SP
dc.description.affiliationUnespDepartamento de Patologia Medical School UNESP—São Paulo State University, SP
dc.description.sponsorshipPró-Reitoria de Pesquisa e Pós-Graduação, Universidade Federal de Ouro Preto
dc.description.sponsorshipUniversidade Federal de Ouro Preto
dc.description.sponsorshipIdPró-Reitoria de Pesquisa e Pós-Graduação, Universidade Federal de Ouro Preto: PROPPI/UFOP Nº 03/2023
dc.description.sponsorshipIdUniversidade Federal de Ouro Preto: PROPPI/UFOP Nº 03/2023
dc.identifierhttp://dx.doi.org/10.3390/molecules28052412
dc.identifier.citationMolecules, v. 28, n. 5, 2023.
dc.identifier.doi10.3390/molecules28052412
dc.identifier.issn1420-3049
dc.identifier.scopus2-s2.0-85149886329
dc.identifier.urihttp://hdl.handle.net/11449/248507
dc.language.isoeng
dc.relation.ispartofMolecules
dc.sourceScopus
dc.subjectbladder cancer
dc.subjectJHDM1D-AS1
dc.subjectlong non-coding RNAs
dc.titleLncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cellsen
dc.typeArtigo
unesp.author.orcid0000-0001-9751-3379[2]
unesp.author.orcid0000-0003-0271-0519[4]
unesp.author.orcid0000-0002-2615-7730[6]

Arquivos

Coleções

Artigos - Patologia - FMB